Table 1.
Clinical and Pathological Demographic Information
| PET Positive for Metastasis |
PET Negative for Metastasis |
P value* |
||
|---|---|---|---|---|
| Patients (N) | 107 | 36 | 71 | |
|
| ||||
| Age (years) | ||||
|
| ||||
| Median (range) |
61 (46-80) |
61.5 (47-78) |
61 (46-80) |
0.9544 |
|
| ||||
| PSA (ng/mL) | ||||
|
| ||||
| Median (range) |
11.8 (1.4-225.4) |
11.25 (1.4-82.4) |
11.9 (2.9-225.4) |
0.3556 |
|
| ||||
|
Clinical
Stage (N) |
105* | 35 | 70 | |
|
| ||||
| T1 | 70 (66.7%) | 21 (60.0%) | 49 (70.0%) | 0.2909 |
|
| ||||
| T2 | 34 (32.4%) | 13 (37.1%) | 21 (30.0%) | |
|
| ||||
| T3 | 1 (0.9%) | 1 (2.9%) | 0 (0.0%) | |
|
| ||||
|
Biopsy
Gleason Score (N) |
107 | 36 | 71 | |
|
| ||||
| 6 | 6 (5.6%) | 1 (2.78%) | 5 (7.04%) | 0.8364 |
|
| ||||
| 7 | 38 (35.5%) | 13 (36.11%) | 25 (35.21%) | |
|
| ||||
| 8-10 | 63 (58.9%) | 22 (61.11%) | 41 (57.75%) | |
|
| ||||
|
Prostatecto my Pathology Gleason Score (N) |
102** | 31 | 71 | |
|
| ||||
| 6 | 6 (5.9%) | 1 (3.23%) | 5 (7.0%) | 0.0346 |
|
| ||||
| 7 | 53 (52.0%) | 11 (35.48%) | 42 (59.2%) | |
|
| ||||
| 8-10 | 43 (42.1%) | 19 (61.3%) | 24 (33.8%) | |
|
| ||||
|
Pathological
Stage (N) |
102** | 31 | 71 | |
|
| ||||
| T2 | 41 (40.2%) | 7 (22.58%) | 34 (47.89%) | 0.0273 |
|
| ||||
| T3a | 28 (27.5%) | 9 (29.03%) | 19 (26.76%) | |
|
| ||||
| T3b | 32 (31.4%) | 14 (45.16%) | 18 (25.35%) | |
|
| ||||
| T4 | 1 (1.0%) | 1 (3.23%) | 0 (0.00%) | |
|
Time from
PET/CT to surgery (days) |
106 | 35 | 71 | |
|
| ||||
| Median (range) |
13 (1-290) |
13 (1-290) |
14 (1-79) |
0.3550 |
*
Data unavailable in 2 patients
**102 patients underwent prostatectomy while 5 underwent LN sampling or biopsy only.